MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 30, 2005; DOI: 10.1124/mol.105.019364


0026-895X/06/6904-1115-1124$20.00
Mol Pharmacol 69:1115-1124, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.019364v1
69/4/1115    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guergnon, J.
Right arrow Articles by Garcia, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guergnon, J.
Right arrow Articles by Garcia, A.
Original Article

Use of Penetrating Peptides Interacting with PP1/PP2A Proteins As a General Approach for a Drug Phosphatase Technology

Julien Guergnon, Frédéric Dessauge, Victoria Dominguez, Jean Viallet, Serge Bonnefoy, Victor J. Yuste, Odile Mercereau-Puijalon, Xavier Cayla, Angelita Rebollo, Santos A. Susin, Pierre-Etienne Bost, and Alphonse Garcia

Equipe Phosphatases, Unité de Chimie Organique (J.G., F.D., P.-E.B., A.G.), Logiciels et Banques de Données, Pôle Informatique (V.D.) and Unité d'Immunologie Moléculaire des Parasites, Unité de Recherche Associée 2581, Centre National de la Recherche Scientifique (S.B., O.M.-P.), Institut Pasteur, Paris, France; Laboratoire d'Immunologie Cellulaire et Tissulaire, Institut National de la Santé et de la Recherche Médicale U 543, Hôpital Pitié-Salpêtrière, Paris, France (A.R.); LEDAC Unité Mixte de Recherche Centre National de la Recherche Scientifique, Institut Albert Bonniot Faculté de Médecine, La Tronche, France (J.V.); Apoptose et Système Immunitaire, Institut Pasteur, Unité de Recherche Associée 1961, Centre National de la Recherche Scientifique, Paris, France (V.J.Y., S.A.S.); and Equipe Hypophyse, Unité Mixte de Recherche 6175, Institut National de la Recherche Agronomique, Centre National de la Recherche Scientifique-Université de Tours-Haras Nationaux, Physiologie de la Reproduction et des Comportements, Nouzilly, France (X.C.)

Abstract

Protein phosphatase types 1 (PP1) and 2A (PP2A) represent two major families of serine/threonine protein phosphatases that have been implicated in the regulation of many cellular processes, including cell growth and apoptosis in mammalian cells. PP1 and PP2A proteins are composed of oligomeric complexes comprising a catalytic structure (PP1c or PP2AC) containing the enzymatic activity and at least one more interacting subunit. The binding of different subunits to a catalytic structure generates a broad variety of holoenzymes. We showed here that casein kinase 2{alpha} (Ck2{alpha}) and simian virus 40 small t antigen share a putative common beta-strand structure required for PP2A1 trimeric holoenzyme binding. We have also characterized DPT-sh1, a short basic peptide from Ck2{alpha} that interacted only in vitro with the PP2A-A subunit and behaves as a nontoxic penetrating shuttle in several cultivated human cell lines and chick embryos. In addition, DPT-sh1 specifically accumulated in human red cells infected with Plasmodium falciparum malaria parasites. We therefore designed bipartite peptides containing DPT-sh1 and PP1- or PP2A-interacting sequences. We found that DPT-5, a DPT-sh1-derived peptide containing a short sequence identified in CD28 antigen, interacts with PP2A-B{alpha}, and DPT-7, another DPT-sh1-derived peptide containing a short sequence identified in Bad as a PP1 catalytic consensus docking motif, induce apoptosis in cultivated cell lines. These results clearly indicate that the rational design of PP1/PP2A interacting peptides is a pertinent strategy to deregulate intracellular survival pathways.


Received September 30, 2005; accepted December 29, 2005

Address correspondence to: Alphonse Garcia, Equipe Phosphatases, Unité de Chimie Organique, Institut Pasteur, 25 rue du Dr Roux, 75015 Paris, France. E-mail: agarcia{at}pasteur.fr




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. L. McConnell and B. E. Wadzinski
Targeting Protein Serine/Threonine Phosphatases for Drug Development
Mol. Pharmacol., June 1, 2009; 75(6): 1249 - 1261.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. B. G. Arrighi, C. Ebikeme, Y. Jiang, L. Ranford-Cartwright, M. P. Barrett, U. Langel, and I. Faye
Cell-Penetrating Peptide TP10 Shows Broad-Spectrum Activity against both Plasmodium falciparum and Trypanosoma brucei brucei
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3414 - 3417.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics